• Moderna and Merck reported five year follow up data from the Phase IIb KEYNOTE-942/mRNA-4157-P201 trial of intismeran autogene (mRNA-4157) plus Keytruda in high risk melanoma.
• The personalized mRNA based cancer therapy showed a substantial reduction in the risk of tumor recurrence or death compared with Keytruda alone.
• The long term data highlight sustained efficacy and safety for Moderna’s mRNA cancer vaccine approach.

For Moderna (NasdaqGS:MRNA), this oncology update comes with the stock at about $43.0. The shares are up 8.6% over the past week, 27.2% over 30 days, 39.3% year to date and 19.8% over the past year, while longer three and five year returns show large declines of 78.1% and 71.7% respectively.

This new cancer data gives investors another lens on Moderna’s shift beyond infectious disease vaccines and toward a broader pipeline. The way the company builds on intismeran autogene, both in melanoma and in other tumor types, is likely to be an important factor in how investors evaluate the stock from here.

Stay updated on the most important news stories for Moderna by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Moderna.

Quick Assessment

• ❌ Price vs Analyst Target: At US$43.0, the share price sits above the US$37.4 consensus target.
• ❌ Simply Wall St Valuation: Valuation status is currently unknown, so there is no clear undervalued signal here.
• ✅ Recent Momentum: The stock is up about 27.2% over the last 30 days, showing strong short term momentum.

Check out Simply Wall St's in depth valuation analysis for Moderna.

Key Considerations

• 📊 The melanoma data reinforces Moderna’s push into oncology, which investors may weigh against current revenue of US$2,232.0m and a reported net loss of US$3,116.0m.
• 📊 Watch how this trial progresses into later stage studies, any regulatory milestones and how guidance around the broader pipeline evolves from here.
• ⚠️ One flagged risk is a volatile share price over the past 3 months, which can magnify reactions to future clinical or regulatory updates.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Moderna analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.